A Phase 1 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers

Launched by ALNYLAM PHARMACEUTICALS · Feb 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ALN-4324 to see if it is safe for use in healthy volunteers who are overweight or obese. The main goal is to understand how well the treatment works and how the body processes it when given in single doses. The trial is currently looking for participants aged between 18 and 65 who have a body mass index (BMI) between 27 and 40. This means they are above a healthy weight but not severely obese.

If you or someone you know is interested in participating, you should be generally healthy and not have certain infections like HIV or hepatitis. Participants will receive doses of the treatment and be closely monitored for any side effects to ensure their safety. This trial is an important step in learning more about ALN-4324 and how it could potentially help those who struggle with weight-related health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Has a body mass index (BMI) of ≥27 kg/m\^2 and \<40 kg/m\^2
• Exclusion Criteria:
• • Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
• • Note: other protocol defined inclusion/exclusion criteria apply